Chiron Corporation

Halozyme, Inc.

Philip Lee Sheridan

Gregory Ian Frost

Louis Howard Bookbinder

Ge Wei

Stephen M W Chang

Mordechai Bodner

Lei Huang

Sybille L Sauter

Harold Michael Shepard

Nicholas J DePolo

Lalitha Kodandapani

Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.

Methods for assessing and identifying or evolving conditionally active therapeutic proteins

Retroviral vector particle producing cells are provided, wherein the cell (a) has greater than 5 stably integrated copies of a retroviral vector construct; (b) produces greater than 10 infectious recombinant retroviral vector particles per cell per day; and (c) produces replication incompetent retroviral vector particles.

Methods for producing a vector producing cell line utilizing a high multiplicity of transduction

Growing community of inventors

San Diego, CA, United States of America

Philip Lee Sheridan